EUSA Pharma is a biopharmaceutical company focused on oncology and rare diseases. It offers Sylvant, a product for the treatment of patients with idiopathic multicentric Castleman’s disease (MCD). The company also provides Qarziba for the treatment of high-risk neuroblastoma and Fotivda for the first-line treatment of adult patients with advanced renal cell carcinoma.